New combo therapy aims to stop liver cancer from coming back
NCT ID NCT04912765
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a personalized vaccine made from a patient's own immune cells combined with an immunotherapy drug (nivolumab) to prevent liver cancer or colorectal cancer that has spread to the liver from returning after surgery. About 60 adults with these cancers will receive the treatment. The goal is to see if this approach can improve relapse-free survival and boost the immune system's ability to fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Singapore
RECRUITINGSingapore, 169690, Singapore
Conditions
Explore the condition pages connected to this study.